References
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp 88–93.
- Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.
- van de Loosdrecht AA, Ireland R, Kern W, et al. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 2013;54: 472–475.
- Tang G, Jorgensen JL, Zhou Y, et al. Multi-color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res 2012;36:974–981.
- Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011;108:5009–5014.
- Roth C, Garner K, Ten Eyck S, et al. TIM3 expression by leukemic and non-leukemic myeloblasts. Cytometry B Clin Cytom 2013;84:167–172.
- Sabatos CA, Chakravarti S, Cha E, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003;4:1102–1110.
- Lee J, Park EJ, Noh JW, et al. Underexpression of TIM-3 and blunted galectin-9-induced apoptosis of CD4 + T cells in rheumatoid arthritis. Inflammation 2012;35:633–637.
- Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100:3639–3645.
- Wlodarski MW, Gondek LP, Nearman ZP, et al. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006;108:2632–2641.
- Zheng Z, Qianqiao Z, Qi H, et al. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome. Exp Hematol 2010;38:677–684.
- Warlick ED, Miller JS. Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma 2011;52:2045–2049.
- Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011;71:6567–6571.